Buy Rating Affirmed for Sarepta Therapeutics Amid Strong Elevidys Demand and Strategic Growth Outlook
Solid Biosciences up 10% Following J.P. Morgan Upgrade
Sarepta Therapeutics Analyst Ratings
Sarepta Therapeutics (SRPT) Gets a Buy From Piper Sandler
Needham Reiterates Buy on Sarepta Therapeutics, Maintains $235 Price Target
Sarepta Therapeutics Analyst Ratings
RBC Raises Price Target on Sarepta Therapeutics to $182 From $142, Maintains Sector Perform Rating
Sarepta Therapeutics Analyst Ratings
Sarepta Therapeutics Analyst Ratings
Sarepta Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Biohaven Ltd. (BHVN), Sarepta Therapeutics (SRPT)
RBC Capital Cuts Sarepta to Sector Perform Ahead of FDA Decision
Sarepta Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH) and Sarepta Therapeutics (SRPT)
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Sol-Gel Technologies (SLGL)
Sarepta Therapeutics Analyst Ratings
Sarepta Therapeutics Analyst Ratings
Buy Rating for Sarepta Therapeutics' Elevidys Supported by Positive Regulatory Signals
Sarepta Therapeutics Analyst Ratings
Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target Is $180